• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Association of HLA-A*11:01, -A*24:02, and -B*18:01 with Prostate Cancer Risk: A Case-Control Study.HLA-A*11:01、-A*24:02 和 -B*18:01 与前列腺癌风险的关联:病例对照研究。
Int J Mol Sci. 2023 Oct 20;24(20):15398. doi: 10.3390/ijms242015398.
2
Genetic variation and hitchhiking between structurally polymorphic Alu insertions and HLA-A, -B, and -C alleles and other retroelements within the MHC class I region.结构多态性Alu插入序列与HLA - A、- B和 - C等位基因以及MHC I类区域内其他逆转录元件之间的遗传变异与搭便车效应。
Tissue Antigens. 2011 Nov;78(5):359-77. doi: 10.1111/j.1399-0039.2011.01776.x.
3
Presence of strong association of the major histocompatibility complex (MHC) class I allele HLA-A*26:01 with idiopathic hypoparathyroidism.主要组织相容性复合体 (MHC) Ⅰ类等位基因 HLA-A*26:01 与特发性甲状旁腺功能减退症有很强的关联。
J Clin Endocrinol Metab. 2012 Sep;97(9):E1820-4. doi: 10.1210/jc.2012-1328. Epub 2012 Jun 20.
4
Human leukocyte antigen alleles and susceptibility to psoriatic arthritis.人类白细胞抗原等位基因与银屑病关节炎易感性。
Hum Immunol. 2013 Oct;74(10):1333-8. doi: 10.1016/j.humimm.2013.07.014. Epub 2013 Aug 2.
5
The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles.MHC 呈递的磷酸肽全景为癌症免疫治疗提供了跨多个 HLA 等位基因的可操作共享肿瘤抗原。
J Immunother Cancer. 2023 Sep;11(9). doi: 10.1136/jitc-2023-006889.
6
PGG.MHC: toward understanding the diversity of major histocompatibility complexes in human populations.PGG.MHC:深入了解人类群体中的主要组织相容性复合体多样性。
Nucleic Acids Res. 2023 Jan 6;51(D1):D1102-D1108. doi: 10.1093/nar/gkac997.
7
Haplotype-specific pattern of association of human major histocompatibility complex with non-Hodgkin's lymphoma outcome.人类主要组织相容性复合体与非霍奇金淋巴瘤预后的单倍型特异性关联模式。
Tissue Antigens. 2008 Jan;71(1):16-26. doi: 10.1111/j.1399-0039.2007.00954.x. Epub 2007 Oct 29.
8
Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan.台湾地区HLA I类和II类等位基因及扩展单倍型与鼻咽癌的关联
J Natl Cancer Inst. 2002 Dec 4;94(23):1780-9. doi: 10.1093/jnci/94.23.1780.
9
HLA class I (A, B, C) and class II (DRB1, DQA1, DQB1, DPB1) alleles and haplotypes in the Han from southern China.中国南方汉族人群的HLA I类(A、B、C)和II类(DRB1、DQA1、DQB1、DPB1)等位基因及单倍型
Tissue Antigens. 2007 Dec;70(6):455-63. doi: 10.1111/j.1399-0039.2007.00932.x. Epub 2007 Sep 27.
10
MHC haplotype matching for unrelated hematopoietic cell transplantation.非亲缘造血细胞移植的主要组织相容性复合体单倍型匹配
PLoS Med. 2007 Jan;4(1):e8. doi: 10.1371/journal.pmed.0040008.

引用本文的文献

1
Ancient DNA HLA typing reveals significant shifts in frequency in Europe since the Neolithic.古DNA HLA分型显示,自新石器时代以来,欧洲的频率发生了显著变化。
Sci Rep. 2025 Feb 20;15(1):6161. doi: 10.1038/s41598-024-82449-w.
2
Effect of subcutaneous adipose tissue-associated CSRP2 on the progression of prostate cancer via the WDR5/USP44 pathway.皮下脂肪组织相关的CSRP2通过WDR5/USP44途径对前列腺癌进展的影响
Am J Cancer Res. 2024 Nov 15;14(11):5321-5337. doi: 10.62347/AHQT5920. eCollection 2024.

本文引用的文献

1
Current progress of nanomedicine for prostate cancer diagnosis and treatment.纳米医学在前列腺癌诊断与治疗中的当前进展
Biomed Pharmacother. 2022 Nov;155:113714. doi: 10.1016/j.biopha.2022.113714. Epub 2022 Sep 20.
2
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.靶向前列腺癌中的信号通路:机制与临床试验。
Signal Transduct Target Ther. 2022 Jun 24;7(1):198. doi: 10.1038/s41392-022-01042-7.
3
Prostate cancer disease recurrence after radical prostatectomy is associated with HLA type and local cytomegalovirus immunity.根治性前列腺切除术后前列腺癌复发与 HLA 类型和局部巨细胞病毒免疫有关。
Mol Oncol. 2022 Oct;16(19):3452-3464. doi: 10.1002/1878-0261.13273. Epub 2022 Aug 31.
4
Role of CD8 T lymphocyte cells: Interplay with stromal cells in tumor microenvironment.CD8 T淋巴细胞的作用:与肿瘤微环境中的基质细胞相互作用。
Acta Pharm Sin B. 2021 Jun;11(6):1365-1378. doi: 10.1016/j.apsb.2021.03.027. Epub 2021 Apr 24.
5
TGM4: an immunogenic prostate-restricted antigen.TGM4:一种具有免疫原性的前列腺特异性抗原。
J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2020-001649.
6
Immune Checkpoint Inhibitors in Prostate Cancer.前列腺癌中的免疫检查点抑制剂
Cancers (Basel). 2021 May 2;13(9):2187. doi: 10.3390/cancers13092187.
7
NKX3.1 Localization to Mitochondria Suppresses Prostate Cancer Initiation.NKX3.1 定位于线粒体可抑制前列腺癌的起始。
Cancer Discov. 2021 Sep;11(9):2316-2333. doi: 10.1158/2159-8290.CD-20-1765. Epub 2021 Apr 23.
8
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.通过 MHC I 类抗原呈递丧失实现癌症免疫逃逸。
Front Immunol. 2021 Mar 9;12:636568. doi: 10.3389/fimmu.2021.636568. eCollection 2021.
9
The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.PD-1/PD-L1 阻断在冷肿瘤中的疗效和未来展望。
Clin Immunol. 2021 May;226:108707. doi: 10.1016/j.clim.2021.108707. Epub 2021 Mar 1.
10
Options for Curative Treatment of Localized Prostate Cancer.局限性前列腺癌的根治性治疗选择。
Dtsch Arztebl Int. 2021 Apr 2;118(Forthcoming):228-36. doi: 10.3238/arztebl.m2021.0026.

HLA-A*11:01、-A*24:02 和 -B*18:01 与前列腺癌风险的关联:病例对照研究。

Association of HLA-A*11:01, -A*24:02, and -B*18:01 with Prostate Cancer Risk: A Case-Control Study.

机构信息

Dipartimento di Scienze Biomediche, Università di Sassari, 07100 Sassari, Italy.

Dipartimento di Medicina, Chirurgia e Farmacia, Università di Sassari, 07100 Sassari, Italy.

出版信息

Int J Mol Sci. 2023 Oct 20;24(20):15398. doi: 10.3390/ijms242015398.

DOI:10.3390/ijms242015398
PMID:37895076
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10607162/
Abstract

The major histocompatibility complex (MHC) loci, the most polymorphic regions within the human genome, encode protein complexes responsible for antigen presentation and CD4+ and CD8+ cell activation. In prostate cancer (PCa), the second most diagnosed cancer in the male population, MHC loci undergo significant changes in their expression patterns, which affect the ability of the immune system to attack and eliminate malignant cells. The purpose of this study was to explore the genetic diversity of human leukocyte antigen (HLA)-A and HLA-B in patients with PCa and healthy controls (HCs) by performing HLA genotyping using NGS technology. The analysis highlighted statistically significant differences ( < 0.05) in the prevalence of three alleles (A11:01, A24:02, and B18:01). Among the HCs analyzed, 14.89% had A11:01, 20.21% had A24:02, and 30.61% had B18:01; while 5.21% of patients with PCa presented A11:01, 9.38% presented A24:02, 18.08% presented B18:01. Odds ratio (OR) calculations underlined a negative association between the three alleles and the risk of PCa (OR < 1). The results presented in this study suggest a protective role of A11:01, A24:02, and B18:01 in PCa.

摘要

主要组织相容性复合体(MHC)基因座是人类基因组中多态性最高的区域,其编码的蛋白复合物负责抗原呈递和 CD4+和 CD8+细胞的激活。在前列腺癌(PCa)中,这种男性第二大常见癌症,MHC 基因座的表达模式发生了显著变化,这影响了免疫系统攻击和消除恶性细胞的能力。本研究旨在通过使用 NGS 技术进行 HLA 基因分型,探讨 PCa 患者和健康对照(HC)中人类白细胞抗原(HLA)-A 和 HLA-B 的遗传多样性。分析突出了三个等位基因(A11:01、A24:02 和 B18:01)的流行率存在统计学显著差异(<0.05)。在分析的 HCs 中,14.89%有 A11:01,20.21%有 A24:02,30.61%有 B18:01;而 5.21%的 PCa 患者有 A11:01,9.38%有 A24:02,18.08%有 B18:01。优势比(OR)计算强调了这三个等位基因与 PCa 风险之间的负相关关系(OR<1)。本研究结果表明 A11:01、A24:02 和 B18:01 对 PCa 具有保护作用。